Mercer Global Advisors
CTNM

Mercer Global Advisors’s Contineum Therapeutics CTNM Stock Holding History

Mercer Global Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82K Buy
+355
New +$4.65K ﹤0.01% 5302

Other funds holding CTNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's CTNM Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 355 shares worth $5.82K. The stake represents ﹤0.01% of the portfolio and ranks #5302 among its holdings.

47 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Mercer Global Advisors held 355 shares of Contineum Therapeutics worth $5.82K as of Q2 2026.
  • Contineum Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5302 holding.
  • 47 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.